Renub Research has recently released a report named “Cystic Fibrosis Therapeutics Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Company Analysis” providing a detailed industry analysis that consists of market share insights. In addition, the report covers research on competitors and areas and current advancements in the Cystic Fibrosis Therapeutics Market.
The Cystic Fibrosis Therapeutics Market shall reach US$ 24.35 Billion by 2028.A genetic disorder that impacts the respiratory, digestive, and reproductive systems, cystic fibrosis can be managed with various therapeutic options, including medications, airway clearance techniques, exercise programs, nutritional support, and a lung transplant as a last resort. In addition, recent advances in the field have led to the development of novel therapies like gene therapies and modulators, significantly improving treatment outcomes for individuals with cystic fibrosis.
American Lung Association reports that around 30,000 individuals in the United States and 70,000 individuals worldwide are affected by cystic fibrosis, with approximately 1 in 30 Americans carrying the gene mutation that causes the condition
The growing prevalence of cystic fibrosis is driving demand for treatments. At the same time, medical research has led to the development of innovative therapies, including gene therapies and modulators that improve patient outcomes. As a result, pharmaceutical companies are investing in cystic fibrosis therapeutics due to the potential for market profitability and unmet medical needs. In addition, governments and regulatory agencies are incentivizing research and development and simplifying the approval process, further fuelling growth in the market.
|Historical Period||2017 – 2022|
|Forecast Period||2023 – 2028|
|Segment Covered||Route of Administration, Treatment, Test Type, Distribution, Drug Class, Region|
|Regions Covered||North America, Europe, Asia Pacific, Latin America and Middle East & Africa|
|Companies Covered||Vertex Pharmaceuticals, Abbvie Inc., Novartis Ag, Gilead Sciences, Viatris INC, Pfizer and Astrazeneca|
|Customization Scope||20% Free Customization|
|Post-Sale Analyst Support||1 Year (52 Weeks)|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request)|
During the forecast period, the inhale segment shall capture the largest share of the cystic fibrosis therapeutics market
Inhaling medications provides a targeted and direct approach to treating the respiratory symptoms of cystic fibrosis. Secondly, inhaled therapies allow for higher lung drug concentrations with fewer systemic side effects. Thirdly, patients and physicians prefer inhaled medicines due to their convenience and ease of administration. Finally, advancements in inhalation technology, including nebulizers and dry powder inhalers, have significantly improved drug delivery and efficacy.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=cystic-fibrosis-therapeutics-market-p.php
Route of Administration – Cystic Fibrosis Therapeutics Market Analysis have been Covered from 2 Viewpoints
Devices account for a substantial portion of the revenue in the cystic fibrosis therapeutics market due to their extensive availability and ease of use for patients
Firstly, the growth of the devices segment in the cystic fibrosis therapeutics market is driven by the increasing demand for patient-friendly and portable devices that individuals at home can use. Secondly, the development of more efficient and practical devices, such as smart inhalers and vibrating vests, due to technological advancements is improving treatment outcomes for patients. Thirdly, the demand for devices that can monitor and adjust treatment plans for individual patients, thereby improving efficacy, is driven by the trend towards personalized medicine. Lastly, the increasing prevalence of cystic fibrosis worldwide also significantly contributes to the demand for devices to manage disease symptoms.
Treatment – Cystic Fibrosis Therapeutics Market Analysis have been Covered from 3 Viewpoints
- Other Treatment
Pulmonary function test type holds a significant share in the cystic fibrosis therapeutics market categorized by test type
Pulmonary Function Tests (PFTs) are critical for evaluating lung function in people with cystic fibrosis. They measure lung capacity, airflow, and gas exchange, essential for monitoring disease progression and treatment effectiveness. PFTs are a standard of care in cystic fibrosis diagnosis and management, recommended by medical guidelines for routine clinical practice. They determine appropriate treatment plans and provide valuable information on disease severity. Technological advancements have improved the accuracy and efficiency of PFT devices. Also, the increasing global prevalence of cystic fibrosis drives the demand for PFTs as reliable diagnostic tools.
Test Type – Cystic Fibrosis Therapeutics Market Analysis have been Covered from 5 Viewpoints
- Plumonary Function
- Sweat Calories
- IRT Test
- Faceal Tests
- Genetic Tests
Hospitals dominate the cystic fibrosis therapeutics market due to increasing demand for accurate diagnosis and follow-up treatments under medical supervision
The maximum revenue in the cystic fibrosis therapeutics market is held by hospitals, mainly due to the increasing demand for accurate diagnosis and follow-up treatments under medical supervision. Therefore, there is growth in the number of hospital visits by patients, which drives the development of the hospital segment. Additionally, hospital pharmacies generate significant earnings since patients infected with cystic fibrosis typically visit nearby hospitals for doctor’s appointments and prescription medicines.
Distribution – Cystic Fibrosis Therapeutics Market Analysis have been Covered from 3 Viewpoints
- Retail Pharmacies
CFTR modulators drug class shall generate the highest revenue in the upcoming years
The CFTR Modulators Drug class comprises specialized therapies that improve the functional expression of CFTR mutants, approved for clinical use in people with specific CF genotypes. They have demonstrated high effectiveness in modifying the disease course for most CF patients. Additionally, advanced experimental approaches have been developed to hasten the creation of new modulators, likely to contribute to the growth of the Cystic Fibrosis Therapeutics Market.
Drug Class – Cystic Fibrosis Therapeutics Market Analysis have been Covered from 4 Viewpoints
- Pancreatic Enzyme Supplements
- CFTR Modulators
In the forecast period, North America will have sovereignty in the cystic fibrosis therapeutics market, capturing the largest share
North America’s dominance in the cystic fibrosis therapeutics market can be attributed to various factors, including a higher prevalence of the disease, advanced healthcare infrastructure, favorable regulatory environment for drug development, streamlined drug approval processes by the FDA, technological advancements in cystic fibrosis therapeutics, and high healthcare spending. These factors have created a conducive environment for the development and adoption of innovative therapies and treatments for cystic fibrosis in North America, resulting in the region’s overall revenue dominance in the market.
Region – Cystic Fibrosis Therapeutics Market Analysis have been Covered from 5 Viewpoints
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Vertex Pharmaceuticals, Abbvie Inc., Novartis Ag, Gilead Sciences, Viatris INC, Pfizer, and AstraZeneca are the major players in the Cystic Fibrosis Therapeutics Market.
All companies have been covered from 3 viewpoints
- Recent Developments
- Vertex Pharmaceuticals
- Abbvie Inc.
- Novartis Ag
- Gilead Sciences
- Viatris INC
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)